73 reports

Global Non-Opioid Pain Relief Device Market: Focus on Application, Technology, End-User, Competitive Landscape – Analysis and Forecast, 2018-2029 ## Market Overview ##. ## Pain Management Overview ##. ## Pain Management by Usage of Opioid Drugs ##. ## Pain Management by

  • Opioid
  • Pain Relief
  • Therapy
  • World
  • Forecast

Topical Pain Relief Market - Global Opportunity Analysis and Industry Forecast, 2018-2025 CHAPTER ##: INTRODUCTION ##. ##.

  • OTC
  • Pain Relief
  • APAC
  • World
  • Market Size

Topical Pain Relief Market by Therapeutic Class, Type, Formulation and Distribution Channel - Global Opportunity Analysis and Industry Forecast, 2018-2025 CHAPTER ##: INTRODUCTION ##. ##.

  • OTC
  • Pain Relief
  • APAC
  • World
  • Market Size

Topical Pain Relief Market by Therapeutic Class, Type, Formulation, and Distribution Channel: Opportunity Analysis and Industry Forecast, 2018-2025 CHAPTER ##: INTRODUCTION ##. ##.

  • Pain Relief
  • Pharmaceutical
  • United States
  • Forecast
  • Market Segment
  • EXECUTIVE SUMMARY
  • MAJOR MARKETS CONTINUED

The industry also includes other nonprescription pain-relief products.

  • Analgesic
  • OTC
  • Pain Relief
  • Australia
  • Demand
  • Identifying factors impacting market growth

The overdose of pain-relief medicines can also lead to migraine.

  • Pain Relief
  • Allergan plc
  • Amgen Inc.
  • Eli Lilly & Co Ltd
  • Eli Lilly & Co.
  • common side effect was medication after taste and nausea in
  • Improvement at two hours in people who took LEVADEX compared to Placebo (2nd pivotal trial)

Figure ##: ## hour pain relief & pain free rates in patients treated with LEVADEX (MAP##) compared to placebo (##st pivotal trial) FREEDOM-## Results : Semprana/ Levadex Pivotal Clinical Trials and Results ≤## hour > ## to ≤## hours > ##

  • Clinical Trial
  • Pain Relief
  • World
  • Forecast
  • Allergan plc
  • 7.1.5 RIZAPORT (RIZATRIPTAN BENZOATE)
  • 6.5 JAPAN

SUBJECTS REPORTED PAIN RELIEF IN LESS THAN ## MINUTES, WITH ##% OF SUBJECTS REPORTING PAIN RELIEF WITHIN ONE HOUR OF ADMINISTRATION OF A SINGLE ##MG SUBCUTANEOUS DOSE OF IMITREX INJECTION.

  • Pain Relief
  • Allergan plc
  • Amgen Inc.
  • Eli Lilly & Co.
  • Pfizer Inc.
  • Market challenges

In 2016, the OTC medicines market reached $##. ## billion in the US alone, where the pain relief segment accounted for ##. ##% of overall market share.

  • Pain Relief
  • World
  • Market Size
  • Sigma-Aldrich
  • Thermo Fisher Scientific, Inc.
  • 2.6 Comorbidities and Complications

This class of drugs provides potent pain relief.

  • Pain Relief
  • Market Size
  • Allergan plc
  • Amgen Inc.
  • Depomed, Inc.
  • ANTI-MIGRAINE DRUGS
  • Namenda (memantine)

The company' s Respiratory and Personal Care include Robitussin, Advil Cold & Sinus, Advil Sinus Congestion Relief & Pain, Dimetapp and ChapStick.

  • Hospital
  • Pain Relief
  • AstraZeneca PLC
  • Lilly Endowment Inc.
  • Pfizer Inc.
  • INTRODUCTION
  • REGIONAL OVERVIEW

Sports players also show strong demand for topical pain relief.

  • Analgesic
  • Pain Relief
  • Eastern Europe
  • Demand
  • Forecast
  • LEADING COMPANIES AND BRANDS

Additionally, the company continues to innovate around Nurofen, with Nurofenteen Menta (mint) in Italy, an orodispersible (dissolves in the mouth without the use of water) mint flavoured brand variants targeting teenagers, and its ##-hr Nurofen pain relief patch in the UK for joint

  • Pain Relief
  • Germany
  • Russia
  • Western Europe
  • Demand

No Relief, by Treatment, 2016 The role of food, vitamin and home treatments Table ##-##: Food, Vitamin and Home Treatments Used to Treat Pain: Got Relief vs.

  • OTC
  • Pain Relief
  • DATA PARAMETERS AND REPORT DEFINITIONS (1)
  • REPORT DEFINITIONS (2)

Ibuprofen: Indicated for pain, inflammation and fever, ibuprofen is an NSAID (nonsteroidal anti- Ketoprofen: This is used for the relief of pain and inflammation in rheumatic disease and other musculoskeletal disorders.

  • Pain Relief
  • Demand
  • Bayer AG
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Data parameters and report definitions (1)
  • Report definitions (2)

Different brands accomplish this in different ways: Aleve (Bayer AG), for example, opts for extendedrelease action in its tablets, delivering ## hours of pain relief in one dose of ##mg of naproxen sodium, building on its consistent message of " all day pain

  • Analgesic
  • Pain Relief
  • Therapy
  • World
  • Demand
  • REGIONAL OVERVIEW

PASSPORT ## STEADY REGIONAL GROWTH DRIVEN BY CHINA REGIONAL OVERVIEW The accelerated ageing of the population in China and Japan contributed to the region' s steady growth over the past ## years, as elderly consumers consider pain relief the major and first problem to solve and

  • Pain Relief
  • APAC
  • China
  • Kowa Co., Ltd.
  • Sanofi S.A.

Rising purchase of generic drugs in the Indian market INDIA PAIN MANAGEMENT DRUGS MARKET Rising incidences of chronic pain in the country is one the major factor towards the increasing purchase of generic drugs for relief of pain falling in the category of musculo

  • Pain Relief
  • World
  • AstraZeneca PLC
  • Endo International plc
  • Pfizer Inc.

Pain Relieving Drugs Market Forecast 2017-2027 ##.

  • OTC
  • Pain Relief
  • World
  • Forecast
  • Market Shares
  • PAIN RELIEF DEVICE - PRODUCT DESCRIPTION
  • PAIN RELIEF DEVICE - PRODUCT STATUS

VibraCool uses motion and ice to harness two newly discovered physiologic pain pathways: one mechanical frequency blocks pain, one competes with pain for the brain' s attention.

  • Clinical Trial
  • Pain Relief
  • United States
  • Demand
  • Sanofi S.A.
  • PAIN RELIEF DEVICE - PRODUCT DESCRIPTION
  • PAIN RELIEF DEVICE - PRODUCT STATUS

KAILO IS THE FUTURE OF PAIN RELIEF.

  • Pain Relief
  • Therapy
  • United States
  • Company
  • Demand
  • BAYER HEALTHCARE: YOY REVENUE AND GROWTH RATE OF ASPIRIN 2013-2015 ($ MILLIONS)
  • BAYER HEALTHCARE

These are designed particularly for pain relief.

  • Pain Relief
  • World
  • Bayer AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sep 25, 2019: Aleve demonstrates more pain relief than Acetaminophen for Menstrual Cramps, study shows
  • LATEST CLINICAL TRIALS NEWS ON PRIMARY DYSMENORRHEA

The primary endpoint was patients' ##-hour total pain relief (TOTPAR) scores based on a five-point categorical scalehigher scores indicated greater pain relief.

  • Chronic Disease
  • Pain Relief
  • Pharmaceutical
  • World
  • Product Initiative
  • ALLAY MENSTRUAL PAIN RELIEF PATCH - PRODUCT STATUS
  • ALLAY MENSTRUAL PAIN RELIEF PATCH - PRODUCT DESCRIPTION

Pain ## Carpal Tunnel Syndrome ## Edema ## Hip Arthritis ## Menstrual Pain ## Neck Pain ## Post-Operative Pain ## Shoulder Arthritis ## Indication No of Products BUSINESS DESCRIPTION BIOELECTRONICS CO

  • Pain Relief
  • Therapy
  • United States
  • Product Initiative
  • BioElectronics Corporation

(USA) ##.

  • Pain Relief
  • China
  • United States
  • Demand
  • Market Shares

(USA) ##.

  • Opioid
  • Pain Relief
  • Therapy
  • United States
  • Market Shares
  • Dec 18, 2019: Biohaven reports positive data from migraine trial of vazegepant
  • a liver safety profile similar to placebo.

Pain relief was sustained throughout ## hours.

  • OTC
  • Pain Relief
  • Therapy
  • United States
  • Product Initiative
  • registered with the U.S. National Institutes of Health.
  • Symptom as an Endpoint in an Acute Treatment of Migraine Trial."

The co-primary endpoints of the study will be the proportion of patients who achieve pain relief at ## minutes and the proportion of patients whose pain relief is sustained from ## minutes to ## minutes. ##-Dec-2018 Zosano Pharma Corporation announced that the U. S

  • Pain Relief
  • Therapy
  • United States
  • Product Initiative
  • Zosano Pharma Corporation
  • SEP 05, 2008: NEURAXON'S NXN-188 DEMONSTRATES PAIN RELIEF IN MIGRAINE WITH AURA
  • Neurophyxia B.V. is an innovative clinical stage drug development company, focusing on disorders affecting the newborn child announces the start of formal preclinical development of 2-IB (manufacturing and safety studies).

Study ## reported pain relief as early as ## minutes after dosing, and relief was sustained across the migraine episode.

  • Pain Relief
  • Therapy
  • United States
  • Product Initiative
  • NeurAxon, Inc.
  • SEP 05, 2008: NEURAXON'S NXN-188 DEMONSTRATES PAIN RELIEF IN MIGRAINE WITH AURA
  • SEP 30, 2008: NEUROPHYXIA PROVIDES UPDATE ON PRE-CINICAL STUDY OF 2-IMINOBIOTIN

Study ## reported pain relief as early as ## minutes after dosing, and relief was sustained across the migraine episode.

  • Hospital
  • Pain Relief
  • United States
  • Product Initiative
  • NeurAxon, Inc.